How Mounjaro Injections Work: the dual-receptor mechanism explained

The biggest misconception: Mounjaro isn't just another GLP-1 injection

Most people researching weight-loss injections have heard of GLP-1 medicines, semaglutide being the best-known example. The widespread assumption is that Mounjaro works the same way, just at a higher dose. That's not accurate. Tirzepatide, the active ingredient in Mounjaro, was engineered to bind two different receptors: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). GIP receptors are involved in fat storage, energy balance, and sensitivity to the appetite-suppressing signals GLP-1 sends. When both are activated together, the combined effect on appetite and body weight is greater than either pathway produces alone.

The clinical trial evidence reflects this. In SURMOUNT-1, which enrolled 2,539 adults with obesity, participants at the highest tirzepatide dose saw an average body-weight reduction of around 20–21% over 72 weeks, with some analyses reaching approximately 22.5%, figures that placed tirzepatide ahead of semaglutide in the later head-to-head SURMOUNT-5 trial published in the New England Journal of Medicine. Those results came from the highest maintenance doses; the experience at lower doses, and in individual patients, will differ.

Understanding this dual mechanism also explains why Mounjaro's ingredient profile looks different from earlier injectable treatments and why its clinical results pattern is distinct from single-agonist medicines.

What the injection actually does, step by step

After each weekly injection, tirzepatide enters the bloodstream from the subcutaneous tissue and begins binding to GIP and GLP-1 receptors distributed across the gut, brain, and pancreas. In the gut, gastric emptying slows, food moves through the stomach more gradually, so the physical sensation of fullness lasts longer after a meal. In the brain, signals connected to hunger and reward are dampened; many people find they stop thinking about food as constantly as they once did. In the pancreas, insulin release is enhanced in response to food while glucagon secretion is reduced, which helps stabilise blood sugar after eating.

None of this is willpower. The mechanisms are physiological. Weight is shaped by biology far more than most people are told, and tirzepatide works with those biological systems rather than against them. A question our prescribers hear most weeks is whether the appetite reduction will feel sudden or gradual, the honest answer is that most people notice changes in hunger by the end of the first or second pen, though the full effect builds as the dose increases over several months.

The injection technique itself is simple: a once-weekly subcutaneous injection using the pre-filled KwikPen, rotated between the abdomen, thigh, and upper arm. The NHS tirzepatide page covers the practical steps alongside a detailed side-effect profile worth reading before you start.

Do Mounjaro injections work for everyone, and what affects the outcome?

The clinical trials show consistent average weight reductions, but averages contain a wide range. Some people respond exceptionally well at lower doses; others see more modest results even at the maximum. Several factors influence how the Mounjaro injection works in practice for a given individual: baseline metabolic rate, existing conditions, concurrent medicines, diet quality, and activity levels all play a role. Trials were conducted alongside a reduced-calorie diet and increased physical activity, and clinical guidance reflects that, tirzepatide is licensed as part of a broader lifestyle approach, not as a standalone fix.

Eligibility matters too. The licensed criteria cover adults with a BMI of 30 or above, or 27 and above where at least one weight-related condition is present, hypertension, type 2 diabetes, high cholesterol, and obstructive sleep apnoea are among the qualifying conditions. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. A prescriber assesses the full picture before recommending treatment or a dose change; the relationship between the mechanism and weight-loss outcomes is worth exploring separately if you want the evidence in more depth.

If you're weighing up the broader landscape of injectable and oral treatments available, our weight-loss treatment overview sets out the options clearly. Cost is a practical consideration too, the Mounjaro cost page explains current private pricing and what a legitimate service should include. Treatment is a prescription medicine; a prescriber, not an algorithm, reviews every consultation at nume before anything is approved or dispensed.

Side effects and what to watch for

Because tirzepatide slows gastric emptying, the most common side effects are gastrointestinal: nausea, loose stools, constipation, indigestion, and burping feature most often. They tend to be at their sharpest in the first week or two after a dose increase and settle as the body adapts. Fatigue, headache, and mild injection-site reactions are also reported.

Serious effects are uncommon but real. The MHRA Drug Safety Update issued in January 2026 highlighted acute pancreatitis as an infrequent but potentially serious risk with GLP-1 medicines: severe, persistent stomach pain that spreads to the back (with or without vomiting) is a reason to seek urgent medical help rather than wait for the next appointment. Gallbladder symptoms, signs of dehydration from severe vomiting or diarrhoea, and allergic reactions also warrant prompt attention.

Managing injection-site care is straightforward. Rotating sites each week reduces local reactions, and cleaning the area beforehand is standard practice, alcohol swabs are a simple addition to your routine. If you'd like a closer look at the full range of Mounjaro injections available, including pen sizes and dose options, that page covers everything clearly. Used pens must be disposed of safely in a sharps container, never in household waste. The Patient Information Leaflet inside each KwikPen box covers storage, missed doses, and what to do if things feel off, always the first reference to check, alongside your prescriber.